CR20110275A - 3-aminociclopentancarboxamidas como moduladores del receptor quimiocina - Google Patents

3-aminociclopentancarboxamidas como moduladores del receptor quimiocina

Info

Publication number
CR20110275A
CR20110275A CR20110275A CR20110275A CR20110275A CR 20110275 A CR20110275 A CR 20110275A CR 20110275 A CR20110275 A CR 20110275A CR 20110275 A CR20110275 A CR 20110275A CR 20110275 A CR20110275 A CR 20110275A
Authority
CR
Costa Rica
Prior art keywords
chemiokin
aminociclopentancarboxamids
receptor modulators
compound
formula
Prior art date
Application number
CR20110275A
Other languages
English (en)
Spanish (es)
Inventor
Rajesh Venkateswaran Devraj
Wei Huang
Robert Owen Hughes
Donald Joseph Rogier Jr
John Isidro Trujillo
Steve Ronald Turner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR20110275A publication Critical patent/CR20110275A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
CR20110275A 2008-11-26 2011-05-26 3-aminociclopentancarboxamidas como moduladores del receptor quimiocina CR20110275A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11805308P 2008-11-26 2008-11-26

Publications (1)

Publication Number Publication Date
CR20110275A true CR20110275A (es) 2011-07-01

Family

ID=41693100

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110275A CR20110275A (es) 2008-11-26 2011-05-26 3-aminociclopentancarboxamidas como moduladores del receptor quimiocina

Country Status (38)

Country Link
US (2) US8293903B2 (enExample)
EP (1) EP2370442B9 (enExample)
JP (1) JP5108153B2 (enExample)
KR (1) KR101374412B1 (enExample)
CN (1) CN102227429B (enExample)
AP (1) AP3113A (enExample)
AU (1) AU2009321221B2 (enExample)
BR (1) BRPI0920936A2 (enExample)
CA (1) CA2743030C (enExample)
CL (1) CL2011001223A1 (enExample)
CO (1) CO6361921A2 (enExample)
CR (1) CR20110275A (enExample)
CU (1) CU24022B1 (enExample)
CY (1) CY1114020T1 (enExample)
DK (1) DK2370442T5 (enExample)
DO (1) DOP2011000154A (enExample)
EA (1) EA020470B1 (enExample)
EC (1) ECSP11011081A (enExample)
ES (1) ES2415430T3 (enExample)
GE (1) GEP20146064B (enExample)
HR (1) HRP20130409T2 (enExample)
IL (1) IL212732A (enExample)
MA (1) MA32834B1 (enExample)
ME (1) ME01144B (enExample)
MX (1) MX2011005526A (enExample)
MY (1) MY152557A (enExample)
NI (1) NI201100102A (enExample)
NZ (1) NZ592919A (enExample)
PE (1) PE20110831A1 (enExample)
PL (1) PL2370442T3 (enExample)
PT (1) PT2370442E (enExample)
RS (2) RS52810B9 (enExample)
SI (1) SI2370442T1 (enExample)
SV (1) SV2011003923A (enExample)
TN (1) TN2011000254A1 (enExample)
UA (1) UA99978C2 (enExample)
WO (1) WO2010061329A1 (enExample)
ZA (1) ZA201104069B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0920936A2 (pt) * 2008-11-26 2020-08-11 Pfizer Inc 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas
KR101303963B1 (ko) * 2011-04-08 2013-09-05 재단법인 경기과학기술진흥원 (1ｒ,2ｒ,3ｒ)-3-아미노사이클로펜탄-1,2-디올을 포함하는 항알러지용 조성물
KR102456088B1 (ko) 2014-04-04 2022-10-19 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
TW201605451A (zh) * 2014-07-17 2016-02-16 參天製藥股份有限公司 老年性黃斑部病變之預防或治療劑
JOP20190040A1 (ar) * 2016-09-14 2019-03-10 Novartis Ag توليفة من ناهضات fxr
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲（江蘇）醫藥有限公司 環戊烷化合物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
ATE237342T1 (de) 1994-07-11 2003-05-15 Athena Neurosciences Inc Inhibitoren der leukozytenadhäsion
US5462208A (en) 1994-08-01 1995-10-31 The Procter & Gamble Company Two-phase dispensing systems utilizing bellows pumps
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
AU5259296A (en) 1995-04-07 1996-10-23 Warner-Lambert Company Flavones and coumarins as agents for the treatment of athero sclerosis
US5704960A (en) 1995-12-20 1998-01-06 Corning, Inc. Method of forming an optical fiber for reduced polarization effects in amplifiers
GB9603741D0 (en) 1996-02-22 1996-04-24 Lin Mei Treatment of water by electrolysis
US6281212B1 (en) 1996-07-12 2001-08-28 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds
EP1017382B1 (en) 1997-05-29 2006-03-01 Merck & Co., Inc. (a New Jersey corp.) Biarylalkanoic acids as cell adhesion inhibitors
JP2002512625A (ja) 1997-05-29 2002-04-23 メルク エンド カンパニー インコーポレーテッド 細胞接着阻害薬としての複素環アミド化合物
WO1998053818A1 (en) 1997-05-29 1998-12-03 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
AU7667498A (en) 1997-05-30 1998-12-30 Celltech Therapeutics Limited Anti-inflammatory tyrosine derivatives
ES2206953T3 (es) 1997-06-23 2004-05-16 Tanabe Seiyaku Co., Ltd. Inhibidores de la adherencia celular mediada por alfa 4-beta 1.
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
MY129850A (en) * 2002-04-29 2007-05-31 Merck Sharp & Dohme Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity
SI1501507T1 (sl) * 2002-04-29 2008-12-31 Merck & Co Inc Tetrahidropiranil ciklopentil tetrahidropiridopiridin modulatorji s kemokinsko receptorsko aktivnostjo
MXPA06007000A (es) * 2003-12-18 2006-08-31 Incyte Corp Derivados de 3-cicloalquilaminopirrolidina como moduladores de receptores de quimiocina.
US7435830B2 (en) * 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
US7566726B2 (en) 2004-04-28 2009-07-28 Merck & Co. Inc. 3,3-disubstituted tetrahydropyranyl cyclopentyl amide modulators of chemokine receptor activity
WO2006004741A2 (en) * 2004-06-28 2006-01-12 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
CN1976702A (zh) * 2004-06-28 2007-06-06 因赛特公司 作为趋化因子受体调节剂的3－氨基环戊烷甲酰胺类
GEP20094843B (en) * 2004-06-28 2009-11-25 Incyte Corp 3-aminocyclopentane carboxamides as modulators of chemokine receptors
MEP1008A (xx) 2005-12-21 2010-02-10 Incyte Corp 3-aminociklopentankarboksamidi kao modulatori receptora hemokina
BRPI0920936A2 (pt) * 2008-11-26 2020-08-11 Pfizer Inc 3-aminociclopentanocarboxamidas como moduladores de receptores de quimiocinas

Also Published As

Publication number Publication date
KR101374412B1 (ko) 2014-03-17
CA2743030C (en) 2013-10-22
HRP20130409T2 (hr) 2013-11-22
PT2370442E (pt) 2013-06-27
CL2011001223A1 (es) 2011-09-02
AP3113A (en) 2015-01-31
BRPI0920936A2 (pt) 2020-08-11
DK2370442T5 (da) 2013-09-23
NZ592919A (en) 2013-05-31
SI2370442T1 (sl) 2013-06-28
EA201170721A1 (ru) 2011-12-30
AU2009321221B2 (en) 2013-04-04
NI201100102A (es) 2011-09-27
RS52810B (sr) 2013-10-31
TN2011000254A1 (fr) 2012-12-17
CU20110121A7 (es) 2013-05-31
CO6361921A2 (es) 2012-01-20
WO2010061329A1 (en) 2010-06-03
CA2743030A1 (en) 2010-06-03
AU2009321221A1 (en) 2010-06-03
EP2370442B9 (en) 2013-09-04
MY152557A (en) 2014-10-31
ES2415430T9 (es) 2013-11-25
MA32834B1 (fr) 2011-11-01
GEP20146064B (en) 2014-03-25
RS52810B8 (sr) 2019-08-30
US20110144129A1 (en) 2011-06-16
DK2370442T3 (da) 2013-06-17
KR20110075036A (ko) 2011-07-05
JP2012509931A (ja) 2012-04-26
JP5108153B2 (ja) 2012-12-26
ES2415430T3 (es) 2013-07-25
US20130197008A1 (en) 2013-08-01
PL2370442T3 (pl) 2013-08-30
PE20110831A1 (es) 2011-11-20
IL212732A (en) 2016-06-30
ECSP11011081A (es) 2011-12-30
EA020470B1 (ru) 2014-11-28
ME01144B (me) 2013-03-20
UA99978C2 (en) 2012-10-25
US8946413B2 (en) 2015-02-03
EP2370442B1 (en) 2013-04-24
DOP2011000154A (es) 2011-07-31
IL212732A0 (en) 2011-07-31
EP2370442A1 (en) 2011-10-05
CU24022B1 (es) 2014-07-30
CN102227429A (zh) 2011-10-26
CN102227429B (zh) 2014-05-28
ZA201104069B (en) 2012-02-29
CY1114020T1 (el) 2016-07-27
RS52810B9 (sr) 2019-06-28
US8293903B2 (en) 2012-10-23
HRP20130409T1 (en) 2013-06-30
HK1161261A1 (en) 2012-08-24
AP2011005732A0 (en) 2011-06-30
MX2011005526A (es) 2011-06-06
SV2011003923A (es) 2011-07-28

Similar Documents

Publication Publication Date Title
CR20110432A (es) Pirimidinas fusionadas
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
EA201490518A1 (ru) Пирролбензодиазепины
AU2011232516A8 (en) Chemical compounds
CR20110268A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1
BRPI1012770B8 (pt) derivados de tiofeno
CR11150A (es) Compuestos de bencimidazol
UA107791C2 (en) Pesticidal compositions
CO7400871A2 (es) Compuestos de piridilo sustituidos con heteroarilo útiles como moduladores de cinasa
EA201190179A1 (ru) Способы и промежуточные химические соединения для получения фармацевтических средств
ES2657549T3 (es) Piridopirazinas sustituidas como nuevos inhibidores de SYK
DOP2010000053A (es) Derivados de pirrolidin -2-ona como moduladores del receptor de androgeno
MX2012006233A (es) Nuevos compuestos de espiropiperidina.
ECSP11011244A (es) Nuevos herbicidas.
MY156954A (en) PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSES
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
NI200900151A (es) Nuevo procedimiento de síntesis de la agomelatina.
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
CR20110275A (es) 3-aminociclopentancarboxamidas como moduladores del receptor quimiocina
AR095097A1 (es) Compuestos de fenoxietoxi
DOP2014000250A (es) Nuevos compuestos de pirazol